Sell4

Neumora Therapeutics, Inc.

NMRA

Total Value

$827.5K

Net $270.0K sold

Filing Date

Aug 21, 2026

4 transactions

Sales

$270.0K

4 transactions

Trade Summary

On Aug 20, 2026 through Aug 21, 2026, Aurora Daljit Singh, Insider, sold $827.5K of Neumora Therapeutics, Inc. (NMRA) across 4 transactions. The filing covers Common Stock and reflects net selling of $270.0K. Reported prices ranged from $0.72 to $1.60. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Price at the Time of the Trade

NMRA daily price with the insider's sale marked at $1.53.

Sold in the lower half of the 6-month range · the stock trades 6% higher today.

Price data is delayed and provided for context only — not investment advice.

Insider Information

Name: Aurora Daljit Singh
Role: Insider
Location: WATERTOWN, MA

Filing Details

Filing Date: Aug 21, 2026
Transaction Date: Aug 20, 2026
Accession Number: 0001610717-26-000385
Form Type: 4
Net Trading Amount: -$270.0K

Non-Derivative Transactions

Date	Security	Shares	Price	Type	Value
Aug 20, 2026	Common Stock	67,741	$0.72	Exercise	$48.8K
Aug 20, 2026	Common Stock	67,741	$1.51	Sale	$102.6K
Aug 20, 2026	Common Stock	21,685	$0.72	Exercise	$15.6K
Aug 20, 2026	Common Stock	45,026	$0.72	Exercise	$32.4K
Aug 20, 2026	Common Stock	66,711	$1.51	Sale	$101.0K
Aug 21, 2026	Common Stock	20,553	$0.72	Exercise	$14.8K
Aug 21, 2026	Common Stock	20,553	$1.59	Sale	$32.8K
Aug 21, 2026	Common Stock	21,055	$0.72	Exercise	$15.2K
Aug 21, 2026	Common Stock	21,055	$1.60	Sale	$33.6K

Derivative Transactions

Date	Security	Shares	Exercise Price	Type	Value
Aug 20, 2026	NMRA derivative	67,741	$0.72	Exercise	$48.8K
Aug 20, 2026	NMRA derivative	45,026	$0.72	Exercise	$32.4K
Aug 20, 2026	NMRA derivative	21,685	$0.72	Exercise	$15.6K
Aug 20, 2026	NMRA derivative	200,000	$1.52	Grant/Award	$304.0K
Aug 21, 2026	NMRA derivative	20,553	$0.72	Exercise	$14.8K
Aug 21, 2026	NMRA derivative	21,055	$0.72	Exercise	$15.2K

Want live alerts when Aurora Daljit Singh trades again?

Download Insider Trades to track NMRA, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)This transaction was executed in multiple trades at prices ranging from $1.485 to $1.625, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
(F2)This transaction was executed in multiple trades at prices ranging from $1.48 to $1.6252, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
(F3)Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries.
(F4)25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
(F5)The stock option is fully vested and exercisable.
(F6)25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
(F7)This transaction was executed in multiple trades at prices ranging from $1.51 to $1.6379, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
(F8)This transaction was executed in multiple trades at prices ranging from $1.51 to $1.6393, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aurora Daljit Singh

(Last)

(First)

(Middle)

C/O NEUMORA THERAPEUTICS, INC.

260 ARSENAL PLACE, SUITE 1

(Street)

WATERTOWN

02472

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Neumora Therapeutics, Inc. [ NMRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/20/2026		M		67,741	A	$0.72	116,491	D
Common Stock	08/20/2026		S		67,741	D	$1.5144⁽¹⁾	48,750	D
Common Stock	08/20/2026		M		21,685	A	$0.72	21,685	I	See footnote⁽³⁾
Common Stock	08/20/2026		M		45,026	A	$0.72	66,711	I	See footnote⁽³⁾
Common Stock	08/20/2026		S		66,711	D	$1.514⁽²⁾	0	I	See footnote⁽³⁾
Common Stock	08/21/2026		M		20,553	A	$0.72	69,303	D
Common Stock	08/21/2026		S		20,553	D	$1.5949⁽⁷⁾	48,750	D
Common Stock	08/21/2026		M		21,055	A	$0.72	21,055	I	See footnote⁽³⁾
Common Stock	08/21/2026		S		21,055	D	$1.5958⁽⁸⁾	0	I	See footnote⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$0.72	08/20/2026		M			67,741	⁽⁴⁾	02/14/2034	Common Stock	67,741	$0	109,527	D
Stock Option (Right to Buy)	$0.72	08/20/2026		M			45,026	⁽⁵⁾	01/19/2033	Common Stock	45,026	$0	0	I	See footnote⁽³⁾
Stock Option (Right to Buy)	$0.72	08/20/2026		M			21,685	⁽⁵⁾	09/20/2031	Common Stock	21,685	$0	115,853	I	See footnote⁽³⁾
Stock Option (Right to Buy)	$1.52	08/20/2026		A		200,000		⁽⁶⁾	08/20/2036	Common Stock	200,000	$0	200,000	D
Stock Option (Right to Buy)	$0.72	08/21/2026		M			20,553	⁽⁴⁾	02/14/2034	Common Stock	20,553	$0	88,974	D
Stock Option (Right to Buy)	$0.72	08/21/2026		M			21,055	⁽⁵⁾	09/20/2031	Common Stock	21,055	$0	94,798	I	See footnote⁽³⁾

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $1.485 to $1.625, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

2. This transaction was executed in multiple trades at prices ranging from $1.48 to $1.6252, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries.

4. 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

5. The stock option is fully vested and exercisable.

6. 25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

7. This transaction was executed in multiple trades at prices ranging from $1.51 to $1.6379, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

8. This transaction was executed in multiple trades at prices ranging from $1.51 to $1.6393, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

Title: Chief Operating and Development Officer

	/s/ Michael Milligan, as Attorney-in-Fact for Daljit Singh Aurora	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0001610717-26-000385.

Neumora Therapeutics, Inc.

Trade Summary

Price at the Time of the Trade

Company Information

Insider Information

Filing Details

Non-Derivative Transactions

Derivative Transactions

Want live alerts when Aurora Daljit Singh trades again?

Footnotes

SEC Form 4

SEC Filing

SEC Form 4

Price at the Time of the Trade